John Zhu

553 total citations
17 papers, 418 citations indexed

About

John Zhu is a scholar working on Oncology, Molecular Biology and Epidemiology. According to data from OpenAlex, John Zhu has authored 17 papers receiving a total of 418 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 7 papers in Molecular Biology and 6 papers in Epidemiology. Recurrent topics in John Zhu's work include Peptidase Inhibition and Analysis (7 papers), Pneumocystis jirovecii pneumonia detection and treatment (5 papers) and Antibiotic Resistance in Bacteria (5 papers). John Zhu is often cited by papers focused on Peptidase Inhibition and Analysis (7 papers), Pneumocystis jirovecii pneumonia detection and treatment (5 papers) and Antibiotic Resistance in Bacteria (5 papers). John Zhu collaborates with scholars based in United States, United Kingdom and Australia. John Zhu's co-authors include Martin J. Stone, Menachem Shoham, Xu Hou, Sara Chuang, Theodore S. Widlanski, Étienne Dumont, Odin Naderer, Milena Kurtinecz, Wei Wang and Karen T. Chang and has published in prestigious journals such as The EMBO Journal, Biochemistry and Antimicrobial Agents and Chemotherapy.

In The Last Decade

John Zhu

17 papers receiving 408 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
John Zhu United States 10 235 143 79 49 44 17 418
Alexander Wiedenmann Germany 9 440 1.9× 175 1.2× 40 0.5× 22 0.4× 25 0.6× 12 654
María C. Rodríguez United States 14 416 1.8× 122 0.9× 146 1.8× 76 1.6× 23 0.5× 28 576
Kathleen M. McKenzie United States 8 332 1.4× 78 0.5× 19 0.2× 101 2.1× 15 0.3× 11 439
Mette Prætorius-Ibba United States 17 714 3.0× 156 1.1× 51 0.6× 37 0.8× 58 1.3× 22 865
Midori Ishikawa Japan 11 234 1.0× 110 0.8× 42 0.5× 11 0.2× 98 2.2× 11 563
Bruce A. Maguire United States 11 468 2.0× 42 0.3× 37 0.5× 19 0.4× 17 0.4× 24 618
Lidija Kovačič Slovenia 15 352 1.5× 40 0.3× 36 0.5× 18 0.4× 16 0.4× 26 587
Ru‐Juan Liu China 20 969 4.1× 103 0.7× 33 0.4× 22 0.4× 78 1.8× 47 1.2k
Daniel E. Todd United Kingdom 9 381 1.6× 75 0.5× 32 0.4× 9 0.2× 20 0.5× 10 513
Jun Kuwahara Japan 13 395 1.7× 67 0.5× 56 0.7× 9 0.2× 31 0.7× 22 572

Countries citing papers authored by John Zhu

Since Specialization
Citations

This map shows the geographic impact of John Zhu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Zhu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Zhu more than expected).

Fields of papers citing papers by John Zhu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John Zhu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Zhu. The network helps show where John Zhu may publish in the future.

Co-authorship network of co-authors of John Zhu

This figure shows the co-authorship network connecting the top 25 collaborators of John Zhu. A scholar is included among the top collaborators of John Zhu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John Zhu. John Zhu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Cui, Jing, Myeong Jin Ju, Jun Song, et al.. (2024). Granzyme B degrades extracellular matrix and promotes inflammation and choroidal neovascularization. Angiogenesis. 27(3). 351–373. 6 indexed citations
2.
Brigandi, Richard A., et al.. (2019). A Phase 1 Randomized, Placebo‐Controlled Trial With a Topical Inhibitor of Stearoyl‐Coenzyme A Desaturase 1 Under Occluded and Nonoccluded Conditions. Clinical Pharmacology in Drug Development. 8(3). 270–280. 9 indexed citations
3.
Collins, David, et al.. (2017). Bioequivalence Studies of a Reformulated Dutasteride and Tamsulosin Hydrochloride Combination Capsule and a Commercially Available Formulation. Clinical Pharmacology in Drug Development. 6(5). 508–516. 2 indexed citations
4.
Fossler, Michael J., et al.. (2016). Impact of Formulation on the Pharmacokinetics of Dutasteride: Results from Two Phase I Studies. Clinical Drug Investigation. 36(9). 763–767. 7 indexed citations
5.
Parr, Alan, Chester L. Bowen, Mark D. Coffin, et al.. (2015). Application of a Stable Isotope Approach to Evaluate Impact of Changes in Manufacturing Parameters for an Immediate-Release Tablet. The Journal of Clinical Pharmacology. 56(7). 801–805. 3 indexed citations
6.
Zhu, John, Chester L. Bowen, Odin Naderer, et al.. (2014). Investigation of Metabolism and Disposition of GSK1322322, a Peptidase Deformylase Inhibitor, in Healthy Humans Using the Entero-Test for Biliary Sampling. Drug Metabolism and Disposition. 42(8). 1314–1325. 9 indexed citations
7.
Naderer, Odin, et al.. (2014). The effect of food and formulation on the pharmacokinetics, safety, and tolerability of GSK1322322 in healthy volunteers. Clinical Pharmacology in Drug Development. 4(1). 49–55. 1 indexed citations
8.
Corey, Ralph, Odin Naderer, William O’Riordan, et al.. (2014). Safety, Tolerability, and Efficacy of GSK1322322 in the Treatment of Acute Bacterial Skin and Skin Structure Infections. Antimicrobial Agents and Chemotherapy. 58(11). 6518–6527. 28 indexed citations
9.
Naderer, Odin, et al.. (2013). Single-Dose Safety, Tolerability, and Pharmacokinetics of the Antibiotic GSK1322322, a Novel Peptide Deformylase Inhibitor. Antimicrobial Agents and Chemotherapy. 57(5). 2005–2009. 25 indexed citations
10.
Naderer, Odin, et al.. (2013). Effect of H 2 Blockade and Food on Single-Dose Pharmacokinetics of GSK1322322, a Peptide Deformylase Inhibitor Antibacterial. Antimicrobial Agents and Chemotherapy. 57(6). 2556–2561. 7 indexed citations
11.
Naderer, Odin, Keith A. Rodvold, John Zhu, et al.. (2013). Penetration of GSK1322322 into Epithelial Lining Fluid and Alveolar Macrophages as Determined by Bronchoalveolar Lavage. Antimicrobial Agents and Chemotherapy. 58(1). 419–423. 9 indexed citations
12.
Naderer, Odin, et al.. (2013). Safety, tolerability, and pharmacokinetics of oral and intravenous administration of GSK1322322, a peptide deformylase inhibitor. The Journal of Clinical Pharmacology. 53(11). 1168–1176. 11 indexed citations
13.
Wang, Wei, John Zhu, Karen T. Chang, & Kyung‐Tai Min. (2012). DSCR1 interacts with FMRP and is required for spine morphogenesis and local protein synthesis. The EMBO Journal. 31(18). 3655–3666. 44 indexed citations
14.
Zhu, John, Christopher J. Millard, Justin P. Ludeman, et al.. (2011). Tyrosine Sulfation Influences the Chemokine Binding Selectivity of Peptides Derived from Chemokine Receptor CCR3. Biochemistry. 50(9). 1524–1534. 52 indexed citations
15.
Zhu, John, et al.. (2009). Regulation of Chemokine Recognition by Site-Specific Tyrosine Sulfation of Receptor Peptides. Chemistry & Biology. 16(2). 153–161. 62 indexed citations
16.
Stone, Martin J., Sara Chuang, Xu Hou, Menachem Shoham, & John Zhu. (2009). Tyrosine sulfation: an increasingly recognised post-translational modification of secreted proteins. New Biotechnology. 25(5). 299–317. 134 indexed citations
17.
Zhu, John & Asit Mazumder. (2008). Estimating nitrogen exports in response to forest vegetation, age and soil types in two coastal-forested watersheds in British Columbia. Forest Ecology and Management. 255(5-6). 1945–1959. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Alexander Wiedenmann Breakdown of academic impact, for papers by María C. Rodríguez Breakdown of academic impact, for papers by Kathleen M. McKenzie Breakdown of academic impact, for papers by Mette Prætorius-Ibba Breakdown of academic impact, for papers by Midori Ishikawa Breakdown of academic impact, for papers by Bruce A. Maguire Breakdown of academic impact, for papers by Lidija Kovačič Breakdown of academic impact, for papers by Ru‐Juan Liu Breakdown of academic impact, for papers by Daniel E. Todd Breakdown of academic impact, for papers by Jun Kuwahara
Rankless by CCL
2026